share_log

Impressive Earnings May Not Tell The Whole Story For Shenzhen Kangtai Biological Products (SZSE:300601)

Impressive Earnings May Not Tell The Whole Story For Shenzhen Kangtai Biological Products (SZSE:300601)

令人印象深刻的收益可能無法說明深圳康泰生物製品(SZSE: 300601)的全部情況
Simply Wall St ·  05/03 19:23

Unsurprisingly, Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) stock price was strong on the back of its healthy earnings report. However, we think that shareholders may be missing some concerning details in the numbers.

不出所料,深圳康泰生物製品有限公司's(深圳證券交易所股票代碼:300601)的股價因其健康的收益報告而表現強勁。但是,我們認爲股東們可能遺漏了一些與數字相關的細節。

earnings-and-revenue-history
SZSE:300601 Earnings and Revenue History May 3rd 2024
SZSE: 300601 收益和收入歷史記錄 2024 年 5 月 3 日

How Do Unusual Items Influence Profit?

不尋常的物品如何影響利潤?

To properly understand Shenzhen Kangtai Biological Products' profit results, we need to consider the CN¥215m gain attributed to unusual items. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. Which is hardly surprising, given the name. We can see that Shenzhen Kangtai Biological Products' positive unusual items were quite significant relative to its profit in the year to March 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

爲了正確了解深圳康泰生物製品的盈利業績,我們需要考慮不尋常項目帶來的2.15億元人民幣的收益。雖然我們希望看到利潤增加,但當不尋常的物品做出重大貢獻時,我們往往會更加謹慎一些。當我們計算數千家上市公司的數字時,我們發現,特定年份中不尋常的項目所帶來的提振通常不會在第二年重演。考慮到這個名字,這並不奇怪。我們可以看到,截至2024年3月的一年中,深圳康泰生物製品的正面不尋常項目與其利潤相比相當可觀。在其他條件相同的情況下,這可能會使法定利潤成爲衡量潛在盈利能力的不良指導。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓你想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看根據他們的估計描繪未來盈利能力的交互式圖表。

Our Take On Shenzhen Kangtai Biological Products' Profit Performance

我們對深圳康泰生物製品盈利表現的看法

As we discussed above, we think the significant positive unusual item makes Shenzhen Kangtai Biological Products' earnings a poor guide to its underlying profitability. As a result, we think it may well be the case that Shenzhen Kangtai Biological Products' underlying earnings power is lower than its statutory profit. On the bright side, the company showed enough improvement to book a profit this year, after losing money last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. For example, we've discovered 2 warning signs that you should run your eye over to get a better picture of Shenzhen Kangtai Biological Products.

正如我們上面討論的那樣,我們認爲這一重大利好不尋常的項目使深圳康泰生物製品的收益無法衡量其潛在盈利能力。因此,我們認爲深圳康泰生物製品的潛在盈利能力很可能低於其法定利潤。好的一面是,該公司在去年虧損之後,表現出了足夠的改善,今年實現了盈利。當然,我們只是在分析其收益時才浮出水面;人們還可以考慮利潤率、預測增長和投資回報率等因素。請記住,在分析股票時,值得注意所涉及的風險。例如,我們發現了兩個警告標誌,爲了更好地了解深圳康泰生物製品,你應該仔細檢查一下。

Today we've zoomed in on a single data point to better understand the nature of Shenzhen Kangtai Biological Products' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

今天,我們放大了單一數據點,以更好地了解深圳康泰生物製品利潤的性質。但是,如果你能夠將注意力集中在細節上,總會有更多的事情需要發現。有些人認爲高股本回報率是優質業務的好兆頭。雖然可能需要你進行一些研究,但你可能會發現這份免費收集的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論